ReviewPharmacoEconomics2011
Modelling the epidemiology of infectious diseases for decision analysis: a primer.
Review in PharmacoEconomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 13 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 13 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Incorporating Social Determinants of Health in Infectious Disease Models: A Systematic Review of Guidelines.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Pooled it
- Do COVID-19 Infectious Disease Models Incorporate the Social Determinants of Health? A Systematic Review.Public health reviews · 2024Pooled it
- Modelling Methods of Economic Evaluations of HIV Testing Strategies in Sub-Saharan Africa: A Systematic Review.Applied health economics and health policy · 2023Pooled it
- Guidelines for multi-model comparisons of the impact of infectious disease interventions.BMC medicine · 2019Guideline
- Dynamic Models of Infectious Disease Transmission in Prisons and the General Population.Epidemiologic reviews · 2018Pooled it
- Lessons from a decade of individual-based models for infectious disease transmission: a systematic review (2006-2015).BMC infectious diseases · 2017Pooled it
- Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.PharmacoEconomics · 2016Pooled it
- Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review.Health economics · 2016Pooled it
- Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Clinical drug investigation · 2015Pooled it
- Use of DALYs in economic analyses on interventions for infectious diseases: a systematic review.Epidemiology and infection · 2015Pooled it
- Systematic narrative review of decision frameworks to select the appropriate modelling approaches for health economic evaluations.BMC research notes · 2015Pooled it
- Modelling the transmission of healthcare associated infections: a systematic review.BMC infectious diseases · 2013Pooled it
- Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries.BMC public health · 2012Pooled it
- Article
- Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.Human vaccines & immunotherapeutics · 2024Article
- The role of economic evaluation in modelling public health and social measures for pandemic policy: a systematic review.Cost effectiveness and resource allocation : C/E · 2024Article
- Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA.Applied health economics and health policy · 2024Article
- The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.BMC medicine · 2023Article
- Modeling the potential health impact of prospective Strep A vaccines.NPJ vaccines · 2023Article
- Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.The International journal on drug policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The number of economic evaluations related to infectious disease topics has increased over the last 2 decades. However, many such evaluations rely on models that do not take into account unique features of infectious diseases that can affect the estimated value of interventions against them. These include their transmissibility from infected to susceptible individuals, the possibility of acquiring natural immunity following recovery from infection and the uncertainties that arise as a result of their complex natural history and epidemiology. Modellers conducting economic evaluations of infectious disease interventions need to know the main features of different types of infectious disease models, the situations in which they should be applied and the effects of model choices on the cost effectiveness of interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.